Wegovy Pill Side Effects: What to Expect from Oral Semaglutide

Wegovy Pill Side Effects: What to Expect from Oral Semaglutide

At the time of this update, Wegovy® tablets have been approved by the MHRA in the UK for weight loss and weight management. Side-effect information on this page is based on the published OASIS-4 trial, the established safety profile of semaglutide, and current UK medicine-safety guidance. We will update this page if the UK product information changes or when Lyv availability is confirmed.

Most patients tolerate oral semaglutide well once they are established on treatment. The first few weeks, and every dose step-up, are usually the more difficult periods. Understanding what to expect — and what to do about each effect — is the difference between continuing treatment successfully and stopping before the medicine has had a chance.

This page covers what is common, what is rare but serious, and what to do in each case. None of this replaces a conversation with your prescriber — but it should help you have a more useful one.

For wider treatment context, visit Lyv’s weight-loss treatment page.

The most common side effects

By a wide margin, the most common side effects of the Wegovy pill are gastrointestinal. This is consistent with the wider GLP-1 medicine class and with oral semaglutide trial data.

• Nausea — usually mild to moderate. Most common in the first weeks of treatment or after a dose increase.
• Diarrhoea — may occur after the first few doses at a new dose level.
• Constipation — can become more noticeable as appetite and food intake reduce.
• Vomiting — less common than nausea, but can be triggered by eating too much or too quickly during dose escalation.
• Abdominal pain or discomfort — usually related to slower digestion and changes in eating pattern.
• Decreased appetite — this is the intended therapeutic effect, but some patients experience it as uncomfortably strong, especially early on.
• Tiredness, headache or dizziness — less common and usually mild, but should be discussed if persistent or severe.

The pattern is important: most gastrointestinal side effects are mild to moderate, occur in the early weeks of each new dose, and improve as the body adapts. They tend to be most noticeable during dose increases and less noticeable once treatment is stable.

For a related GLP-1/GIP side-effect guide, read Lyv’s article on Mounjaro side effects in the UK.

How side effects evolve as the dose steps up

The Wegovy pill's step-up schedule is designed to minimise side effects by giving the gastrointestinal system time to adapt before the next increase. In practice, many patients experience a small increase in nausea, fullness or altered digestion for a few days after each step, followed by a return toward baseline.

Two patterns are common and are not usually cause for alarm:

• A return of nausea after a dose increase, lasting several days and then settling.
• A change in bowel habit — sometimes looser, sometimes firmer — that improves as the body adjusts.

Two patterns warrant a conversation with your pharmacist or prescriber:

• Side effects that do not settle after a reasonable adjustment period at a new dose.
• Side effects severe enough to affect hydration, nutrition or day-to-day function, such as sustained vomiting or inability to eat anything.

Severe symptoms are not a sign that the medicine is “working harder”. They may be a sign that the dose is not currently tolerated and needs clinical review.

Serious but rare side effects

A small number of side effects are rare but require urgent attention.

• Pancreatitis. Severe, persistent abdominal pain, especially if it radiates to the back and is accompanied by nausea or vomiting, needs same-day medical advice.
• Gallbladder problems. Rapid weight loss is a risk factor for gallstones and gallbladder inflammation. Persistent right-upper-abdominal pain, especially after eating, should be reviewed clinically.
• Severe allergic reactions. Swelling of the face, lips, tongue or throat, or difficulty breathing, requires emergency care.
• Hypoglycaemia. Low blood sugar is not common when semaglutide is used alone, but it can become more likely if it is combined with insulin or sulfonylurea medicines for diabetes. Symptoms can include sweating, shakiness, confusion, hunger and dizziness.
• Diabetic retinopathy progression. This is most relevant to patients with pre-existing diabetic retinopathy. Rapid improvement in blood sugar control can sometimes affect eye disease, so patients with this history should discuss monitoring with their clinician.
• Thyroid C-cell tumour warning. GLP-1 receptor agonists are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

If you are unsure whether a symptom is serious, err on the side of caution and contact your pharmacist, prescriber, NHS 111 or emergency services as appropriate.

How the oral side-effect profile compares to the injection

Both formulations share the same overall profile because the molecule is the same: semaglutide. The difference is how the medicine is taken and absorbed.

There are two profile-level differences worth knowing.

The pill is taken daily; the injection is weekly. This may produce a more constant pattern of side effects for some patients during early treatment, rather than the weekly rhythm some people experience with injections.

The pill depends on an empty stomach for absorption. If the dosing rules are not followed, you may experience both reduced effectiveness and more gastrointestinal discomfort. The injection has no equivalent empty-stomach rule.

Injection-site reactions — redness, itching or a small lump at the site — are specific to injections and do not apply to the pill.

For a full comparison, read Lyv’s guide to Wegovy pill vs injection in the UK.

Practical ways to reduce side effects

The single most effective thing you can do to minimise side effects is to follow the dosing rules precisely. Take the tablet on an empty stomach, with only a small amount of water, and wait before eating, drinking anything else or taking other oral medication. Departures from the protocol can reduce the medicine's effect and increase the chance of gastrointestinal symptoms.

Eat slowly. Stop when full. The medicine slows gastric emptying — what used to feel like a normal portion may now feel like overeating, and overeating while on a GLP-1 medicine can produce predictable nausea and discomfort.

Drink water throughout the day. Reduce or avoid alcohol during dose escalations, especially if nausea is present.

If you experience nausea, simple steps may help:

• Eat smaller meals more frequently.
• Avoid fatty, greasy or fried food.
• Eat slowly and stop as soon as you feel full.
• Try bland foods during difficult days.
• Use ginger tea or ginger biscuits if these suit you.

For constipation, increase dietary fibre gradually, stay well hydrated and keep moving with gentle exercise. If it persists, a pharmacist can advise on suitable over-the-counter options.

If symptoms are severe or worsening, contact your prescriber rather than stopping the medicine unilaterally. There may be options such as staying at a lower dose for longer, delaying a step-up, reviewing other medicines, or considering an alternative treatment.

When to contact your prescriber

Seek same-day advice or urgent help if you experience:

• Severe, persistent abdominal pain, especially if it radiates to the back.
• Persistent vomiting that prevents you from keeping water down.
• Signs of an allergic reaction, including facial swelling or breathing difficulty.
• Signs of severe hypoglycaemia, especially if you also take insulin or sulfonylureas.

Contact your pharmacist or prescriber within a few days if you experience:

• Side effects that are not settling after a dose increase.
• Persistent nausea or vomiting affecting nutrition or hydration.
• Right-upper-abdominal pain, especially after meals.
• Mood changes, persistent low mood or any new mental-health concerns.

Raise at your next routine review:

• Manageable but bothersome side effects that have not fully resolved.
• Questions about whether to step up at the next scheduled increase.
• Concerns about the pace of weight loss.

Who should not take the Wegovy pill?

The Wegovy pill may not be suitable for everyone. It is contraindicated or should be avoided in people with:

• A personal or family history of medullary thyroid carcinoma.
• Multiple endocrine neoplasia syndrome type 2.
• A history of pancreatitis, unless carefully reviewed by a prescriber.
• Pregnancy, planned pregnancy or breastfeeding.

It should be used with particular caution in people with:

• Severe gastrointestinal disease, including gastroparesis.
• Severe renal impairment.
• Concomitant insulin or sulfonylurea use because of hypoglycaemia risk.
• Pre-existing diabetic retinopathy.
• Recent major gastrointestinal surgery.

A Lyv pharmacist will check all of these factors during the clinical assessment. If a contraindication is present, we will not prescribe — and we will explain why rather than just refuse.

Sources and further reading

• MHRA: First GLP-1 tablet for weight loss approved in the UK
• Wharton S et al. Oral semaglutide 25 mg in adults with obesity or overweight
• New England Journal of Medicine: Oral semaglutide 25 mg trial data
• BNF: Semaglutide
• NHS Inform: Diabetes and weight-loss medication side effects
• MHRA Yellow Card scheme

MHRA disclaimer

Wegovy is a prescription-only medicine. The decision to prescribe is made by an independent UK-registered prescriber after a clinical assessment.

This article is general information for UK adults and is not a substitute for personalised medical advice. Prescription-only medicines mentioned are supplied only after a clinician-led consultation through a regulated pharmacy. If you have urgent symptoms or concerns about a medicine, speak to your GP, pharmacist, NHS 111 or emergency services as appropriate.